Skip to main content
Chemomab Therapeutics Ltd. logo

Chemomab Therapeutics Ltd. — Investor Relations & Filings

Ticker · CMMB ISIN · US16385C1045 US Manufacturing
Open in API
Filings indexed 332 across all filing types
Latest filing 2021-05-10 Director's Dealing
Country US United States of America
Listing US CMMB

About Chemomab Therapeutics Ltd.

https://www.chemomab.com/

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's scientific platform is based on the discovery of the soluble protein CCL24's central role in driving the cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class monoclonal antibody designed to neutralize CCL24, thereby interfering with the primary pathways that promote these conditions. Nebokitug has demonstrated disease-modifying potential in multiple clinical trials and has received Orphan Drug and Fast Track designations from the U.S. FDA for the treatment of primary sclerosing cholangitis (PSC). Following positive Phase 2 results, the company is preparing for a potential Phase 3 trial for nebokitug in PSC.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2021-05-10 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The provided document text appears to be heavily encoded or corrupted, containing mostly non-readable characters and no discernible financial, regulatory, or corporate information. There are no clear references to any report titles, fiscal periods, regulatory bodies, or keywords that would indicate a specific filing type. The document length is 15,000 characters, which is substantial, but the content does not contain meaningful text to classify as a financial or corporate report. Given the lack of identifiable content and the fallback rule, the document should be classified as a Regulatory Filing (RNS), which serves as a catch-all category for filings that do not fit other specific types.
2021-05-05 English
FORM S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC). It is a registration statement under the Securities Act of 1933 for the offering of securities including ordinary shares, ADSs, debt securities, warrants, and units. The document includes a base prospectus and a sales agreement prospectus, describing the terms and conditions of the securities to be offered. It is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update filings.
2021-04-30 English
424B3
Capital/Financing Update Classification · 100% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to the resale of American Depositary Shares (ADSs) and warrants by selling shareholders. It includes detailed information about the securities being offered, the selling shareholders, the merger background, risk factors, and other disclosures typical of a prospectus. The document is not an annual report, earnings release, or any other financial report but rather a registration statement prospectus for resale of securities. This fits the definition of a Capital/Financing Update (CAP) as it relates to updates on company fundraising and capital structure changes through resale of shares and warrants. The document length and content confirm it is the actual prospectus, not just an announcement of a report.
2021-04-29 English
Regulatory Filings 2021
Regulatory Filings
2021-04-29 English
Regulatory Filings 2021
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC Division of Corporation Finance regarding a request to accelerate the effectiveness of a Registration Statement on Form S-3. It is a formal correspondence related to a regulatory filing process, specifically about the timing of the registration statement becoming effective. The document does not contain financial data, audit information, or report content itself, but rather is a procedural request related to a capital markets filing. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-04-26 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.